Vericel Corp 8K

Vericel Corporation reported strong Q2 2026 financial results, raised full-year 2026 revenue guidance, and announced a $200 million share repurchase program authorized by its Board of Directors.

Vericel Corporation reported strong second quarter 2026 results with total revenue up 22% year-over-year to $77.5 million, driven by 23% growth in MACI revenue and 22% growth in Burn Care revenue, and generated net income of $2.2 million and free cash flow of $14.3 million, while maintaining a strong balance sheet with approximately $227 million in cash and investments and no debt. Based on this performance, the company raised its full-year 2026 revenue guidance to a range of $330–$340 million (with higher MACI and Burn Care revenue expectations), reaffirmed guidance for approximately 75% gross margin and 27% adjusted EBITDA margin, and announced that its Board of Directors has authorized a $200 million share repurchase program as its first capital return initiative. Operationally, the company highlighted record MACI and NexoBrid revenues, continued double-digit growth in MACI biopsies and implants, Epicel revenue growth, and submission of a MACI marketing authorization application to the U.K. MHRA, and it scheduled an investor conference call on July 30, 2026 to discuss these results and updates.

Filing Facts

CIK

887359

Ticker

VCEL

Form

8K

Source Type

fda

Accession

0001628280-26-050815

Alert Tier

7